# MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)

> **NCT00371007** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 126 (—)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks
- **DRUG:** Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks

## Key facts

- **NCT ID:** NCT00371007
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06-01
- **Primary completion:** 2005-04-25
- **Final completion:** 2005-04-25
- **Target enrollment:** 126 (—)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00371007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00371007, "MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00371007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*